BridgeBio Pharma Inc
(NAS:BBIO)
$
26.02
-0.17 (-0.65%)
Market Cap: 4.89 Bil
Enterprise Value: 6.17 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 44/100 BridgeBio Pharma Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 03:00PM GMT
Release Date Price:
$30.6
(-0.58%)
Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst
Hello, everyone. Welcome to the morning session of Day 3 of the Bank of America Virtual Vegas Healthcare Conference. I'm Greg Harrison, U.S. biopharma analyst here at BofA. And I'm very excited that we have BridgeBio here with us today. My colleague, Jason Zemansky, is on the line as well.
And here to speak on behalf of BridgeBio is CEO, Neil Kumar. The format is fireside chat. So feel free to send me questions, and I can ask them anonymously.
So Neil, let's jump right into the Q&A
Questions & Answers
Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst
Maybe you could just give us kind of an overview of your approach to development? And how your platform can potentially offer a higher probability of success in your programs?
Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director
Yes. Sure, happy to. Let me start by thanking you and the entire BAML team for the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot